

# pipeline

spreading risk across various therapeutic areas and across various development stages.

Therapeutic area	Drug	Action	Disease/ condition	Stage	Estimated date	Partner
<b>Cardiovascular</b>	Generic fondaparinux	Indirect factor Xa inhibitor	VTE	ANDA filed and accepted	2009 CY / FDA approval 2009 CY / Market launch	Dr Reddy's
<b>Oncology</b>	HA-Irinotecan	Topoisomerase I inhibitor	Colorectal cancer	Clinical - Ph III IND accepted by the US FDA	2010 CY / Commence Phase III	
<b>Oncology</b>	HyACT <sup>®</sup> antibodies	Various	Cancer	Preclinical	-	
<b>Neuroscience</b>	VAST <sup>®</sup> various	Opioid agonist	Pain	Discovery	-	University of Queensland
<b>Neuroscience</b>	VAST <sup>®</sup> various	MCHR1 antagonist	Obesity	Discovery	Program suspended due to funding constraints	
<b>Respiratory</b>	VAST <sup>®</sup> various	Undisclosed	Respiratory	Discovery	Program suspended due to funding constraints	

**Discovery** - chemical compounds with possible therapeutic benefit in man are identified

**Preclinical** - compound/treatments are tested to measure efficacy and safety prior to testing in humans

**Clinical** - structured studies are conducted in a hospital or clinic in which a drug is evaluated for its effects on humans